Table 7.
Univariate and multivariate analysis for the parameters affecting β1-Integrin expression in malignant tissue samples (n = 60).
| β1-Integrin malignant | Univariate |
#Multivariate |
||
|---|---|---|---|---|
| P | OR (95%C.I) | P | OR (95%C.I) | |
| Age (years) | 0.040* | 0.927*(0.86–0.99) | 0.084 | 0.934 (0.864–1.009) |
| Affected lymph node | 0.655 | 1.025 (0.91–1.14) | ||
| Molecular type | ||||
| Luminal | 0.999 | – | ||
| Triple negative | 0.999 | – | ||
| HER2 Positive | 0.919 | 1.08 (0.24–4.79) | ||
| Metacentric | 0.283 | 0.357 (0.054–2.34) | ||
| Carcinoma in situ | 0.368 | 3.0 (0.27–32.7) | ||
| ER | 0.999 | – | ||
| PR | 0.999 | – | ||
| HER2/neu | 0.919 | 1.08 (0.24–4.79) | ||
| Hb (g/dl) | 0.202 | 0.658 (0.346–1.25) | ||
| WBCs ( × 10³/μl) | 0.806 | 1.054 (0.69–1.60) | ||
| Platelets ( × 10³/μl) | 0.534 | 1.006 (0.988–1.02) | ||
| CA 15–3 (IU/ml) | 0.221 | 1.09 (0.948–1.25) | ||
| EMP2 (Normal)(>0.22) | 0.466 | 0.583 (0.137–2.48) | ||
| EMP2 (Malignant) (>5.84) | 0.033* | 5.50*(1.145–26.41) | 0.076 | 4.522 (0.852–23.98) |
| β1-Integrin (Benign) (>0.70) | 0.466 | 0.58 (0.13–2.48) | ||
$: Reference (I + II), OR: Odd's ratio, C.I: Confidence interval.
#: All variables with p < 0.05 was included in the multivariate.
*: Statistically significant at p ≤ 0.05.